

Georg Mn Behrens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8670655/publications.pdf>

Version: 2024-02-01

98
papers

8,326
citations

117453

34
h-index

53109

85
g-index

115
all docs

115
docs citations

115
times ranked

12134
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3.	2.4	9
2	Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy. <i>HIV Medicine</i> , 2022, 23, 558-563.	1.0	47
3	Similar humoral immune responses in peritoneal dialysis and haemodialysis patients after two doses of the SARS-CoV-2 vaccine BNT162b2. <i>Peritoneal Dialysis International</i> , 2022, 42, 100-101.	1.1	10
4	The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. <i>Cell</i> , 2022, 185, 447-456.e11.	13.5	736
5	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2022, 13, 863039.	2.2	10
6	Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. <i>HIV Medicine</i> , 2022, 23, 849-858.	1.0	57
7	Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects. <i>Biomedicines</i> , 2022, 10, 693.	1.4	1
8	Close to Zero, but Not Zero: What Is an Acceptable HIV Transmission Risk Through Breastfeeding?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, e42-e42.	0.9	3
9	Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination. <i>Emerging Infectious Diseases</i> , 2022, 28, 743-750.	2.0	18
10	Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process. <i>HIV Medicine</i> , 2022, 23, 639-649.	1.0	3
11	SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination. <i>Cell Reports</i> , 2022, 39, 110754.	2.9	5
12	Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 766-767.	4.6	79
13	SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study. <i>BMC Infectious Diseases</i> , 2022, 22, 403.	1.3	10
14	Self-reported Tinnitus and Vertigo or Dizziness in a Cohort of Adult Long COVID Patients. <i>Frontiers in Neurology</i> , 2022, 13, 884002.	1.1	13
15	SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. <i>Cell Host and Microbe</i> , 2022, 30, 1103-1111.e6.	5.1	38
16	Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2. , 2022, , .		0
17	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. <i>Cellular and Molecular Immunology</i> , 2021, 18, 936-944.	4.8	98
18	Beyond Viral Suppression. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab044.	0.4	0

#	ARTICLE	IF	CITATIONS
19	COVID-19 immune signatures reveal stable antiviral T _H cell function despite declining humoral responses. <i>Immunity</i> , 2021, 54, 340-354.e6.	6.6	177
20	Influence of the Antiretroviral Regimen on the Early Changes in Plasma HIV RNA and Immune Activation at Initiation of Antiretroviral Therapy in Naïve HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, e146-e149.	0.9	0
21	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 73, 2000-2008.	2.9	30
22	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , 2021, 12, 4450.	5.8	67
23	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415.	2.9	206
24	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. <i>Nature Medicine</i> , 2021, 27, 1525-1529.	15.2	363
25	Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2455-2456.	4.8	35
26	Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. <i>EBioMedicine</i> , 2021, 70, 103524.	2.7	53
27	B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 37, 109825.	2.9	73
28	SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination. <i>Lancet, The</i> , 2021, 398, 1041-1042.	6.3	24
29	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50,342 1,430	4.3	1,430
30	The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2673-2675.	4.8	25
31	Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2557-2559.	4.8	41
32	Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?. <i>Frontiers in Medicine</i> , 2021, 8, 770381.	1.2	14
33	Improving HIV-related care through eHealth. <i>Lancet HIV,the</i> , 2020, 7, e8-e10.	2.1	6
34	Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. <i>Infectious Diseases and Therapy</i> , 2020, 9, 837-849.	1.8	34
35	The Loss of HLA-F/KIR3DS1 Ligation Is Mediated by Hemoglobin Peptides. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8012.	1.8	4
36	Clinical management of ageing people living with HIV in Europe: the view of the care providers. <i>Infection</i> , 2020, 48, 497-506.	2.3	7

#	ARTICLE	IF	CITATIONS
37	Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals. <i>Infection</i> , 2020, 48, 631-634.	2.3	69
38	Plea for multitargeted interventions for severe COVID-19. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1122-1123.	4.6	18
39	Ability to Monitor National Responses to the HIV Epidemic “Beyond Viral Suppression” Findings From Six European Countries. <i>Frontiers in Public Health</i> , 2020, 8, 36.	1.3	2
40	1269. Cohort Profile: The Translational Platform HIV (TP-HIV), a Multicenter Cohort Project in Germany. <i>Open Forum Infectious Diseases</i> , 2019, 6, S456-S457.	0.4	0
41	Pediatric Healthcare Utilization in a Large Cohort of Refugee Children Entering Western Europe During the Migrant Crisis. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4415.	1.2	8
42	Reorienting health systems to care for people with HIV beyond viral suppression. <i>Lancet HIV</i> , the, 2019, 6, e869-e877.	2.1	57
43	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e86-e94.	0.9	53
44	Prevalence and Types of Anemia in a Large Refugee Cohort in Western Europe in 2015. <i>Journal of Immigrant and Minority Health</i> , 2018, 20, 1332-1338.	0.8	13
45	Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. <i>Haematologica</i> , 2018, 103, 857-864.	1.7	27
46	Molecular Epidemiology of the HIV Epidemic in Three German Metropolitan Regions “Cologne/Bonn, Munich and Hannover, 1999”2016. <i>Scientific Reports</i> , 2018, 8, 6799.	1.6	25
47	Healthcare Utilization in a Large Cohort of Asylum Seekers Entering Western Europe in 2015. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2163.	1.2	24
48	Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8 ⁺ T cell proliferation. <i>European Journal of Immunology</i> , 2018, 48, 2042-2054.	1.6	11
49	Pregnancy Related Health Care Needs in Refugees”A Current Three Center Experience in Europe. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1934.	1.2	27
50	Tuberculosis Specific Interferon-Gamma Production in a Current Refugee Cohort in Western Europe. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1263.	1.2	6
51	Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 939-945.	0.8	35
52	Measles, Rubella and Varicella IgG Seroprevalence in a Large Refugee Cohort in Germany in 2015: A Cross-Sectional Study. <i>Infectious Diseases and Therapy</i> , 2017, 6, 487-496.	1.8	23
53	Herpes simplex virus 1 interferes with autophagy of murine dendritic cells and impairs their ability to stimulate CD8 ⁺ T lymphocytes. <i>European Journal of Immunology</i> , 2017, 47, 1819-1834.	1.6	26
54	Norovirus outbreaks in german refugee camps in 2015. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 997-1003.	0.2	9

#	ARTICLE	IF	CITATIONS
55	Tetanus and diphtheria immunity in refugees in Europe in 2015. <i>Infection</i> , 2017, 45, 157-164.	2.3	35
56	The incidence of first-line antiretroviral treatment changes and related factors among HIV-infected sex workers in Nairobi, Kenya. <i>Pan African Medical Journal</i> , 2017, 28, 7.	0.3	7
57	Prevalent neuropathy in a cohort of HIV-infected Kenyan sex workers using antiretroviral drugs. <i>Pan African Medical Journal</i> , 2016, 25, 14.	0.3	6
58	Systematic Review of the Current Literature on Structured Treatment Interruptions in HIV-infected Patients Receiving Antiretroviral Therapy—Implications for Future HIV Cure Trials. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
59	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016, 22, 839-850.	15.2	395
60	Measles, mumps, rubella, and varicella seroprevalence in refugees in Germany in 2015. <i>Infection</i> , 2016, 44, 781-787.	2.3	57
61	An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. <i>PLoS ONE</i> , 2016, 11, e0155406.	1.1	5
62	Inhibition of Autophagic Flux by Salinomycin Results in Anti-Cancer Effect in Hepatocellular Carcinoma Cells. <i>PLoS ONE</i> , 2014, 9, e95970.	1.1	51
63	Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1-Infected Patients with HIV-1 RNA \geq 100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis. <i>AIDS Patient Care and STDs</i> , 2014, 28, 168-175.	1.1	27
64	Thymidine Analogues Suppress Autophagy and Adipogenesis in Cultured Adipocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 543-551.	1.4	18
65	Toll-Like Receptor α 2 Agonist β Allergen Coupling Efficiently Redirects Th2 Cell Responses and Inhibits Allergic Airway Eosinophilia. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 47, 852-863.	1.4	14
66	Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation. <i>Aids</i> , 2012, 26, 1995-2006.	1.0	44
67	Switching to Tenofovir/Emtricitabine from Abacavir/ Lamivudine in HIV-Infected Adults with Raised Cholesterol: Effect on Lipid Profiles. <i>Antiviral Therapy</i> , 2012, 17, 1011-1020.	0.6	45
68	Abacavir and myocardial infarctions. <i>Aids</i> , 2011, 25, 2043-2045.	1.0	4
69	Abacavir and cardiovascular risk. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 9-14.	1.3	33
70	The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. <i>European Journal of Immunology</i> , 2010, 40, 1272-1283.	1.6	37
71	Fc γ 3 receptor-mediated antigen uptake by lung DC contributes to allergic airway hyper-responsiveness and inflammation. <i>European Journal of Immunology</i> , 2010, 40, 1284-1295.	1.6	16
72	Impaired Lung Dendritic Cell Migration and T Cell Stimulation Induced by Immunostimulatory Oligonucleotides Contribute to Reduced Allergic Airway Inflammation. <i>Journal of Immunology</i> , 2009, 183, 3443-3453.	0.4	10

#	ARTICLE	IF	CITATIONS
73	Contribution of Direct and Cross-Presentation to CTL Immunity against Herpes Simplex Virus 1. <i>Journal of Immunology</i> , 2009, 182, 283-292.	0.4	33
74	Impact of boosting for the strength of asthma parameters and dendritic cell numbers in a C57BL/6 model of allergic airway inflammation. <i>Experimental and Toxicologic Pathology</i> , 2008, 60, 425-434.	2.1	7
75	Treatment options for lipodystrophy in HIV-positive patients. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 39-52.	0.9	5
76	A database of naturally occurring human urinary peptides and proteins for use in clinical applications. <i>Nature Precedings</i> , 2007, , .	0.1	0
77	Relationship of Mitochondrial DNA Depletion and Respiratory Chain Activity in Preadipocytes treated with Nucleoside Reverse Transcriptase Inhibitors. <i>Antiviral Therapy</i> , 2007, 12, 205-216.	0.6	27
78	Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. <i>Nature Immunology</i> , 2006, 7, 165-172.	7.0	308
79	The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 10729-10734.	3.3	357
80	Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. <i>New England Journal of Medicine</i> , 2005, 352, 1721-1722.	13.9	12
81	Helper Requirements for Generation of Effector CTL to Islet I ² Cell Antigens. <i>Journal of Immunology</i> , 2004, 172, 5420-5426.	0.4	56
82	Helper T cells, dendritic cells and CTL Immunity. <i>Immunology and Cell Biology</i> , 2004, 82, 84-90.	1.0	101
83	Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. <i>Immunological Reviews</i> , 2004, 199, 9-26.	2.8	641
84	Clinical impact of HIV-related lipodystrophy and metabolic abnormalities on cardiovascular disease. <i>Aids</i> , 2003, 17, S149-S154.	1.0	35
85	Pathogenesis of the HAART-Associated Metabolic Syndrome. , 2003, 40, 83-96.		2
86	Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. <i>Journal of Clinical Investigation</i> , 2002, 110, 1319-1327.	3.9	57
87	Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. <i>Journal of Clinical Investigation</i> , 2002, 110, 1319-1327.	3.9	30
88	Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. <i>Aids</i> , 2001, 15, 2407-2414.	1.0	212
89	CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. <i>European Journal of Immunology</i> , 2001, 31, 3121-3126.	1.6	410
90	Immune Reconstitution Syndromes in Human Immunodeficiency Virus Infection Following Effective Antiretroviral Therapy. <i>Immunobiology</i> , 2000, 202, 186-193.	0.8	59

#	ARTICLE	IF	CITATIONS
91	Lipodystrophy Syndrome in HIV Infection. <i>Drug Safety</i> , 2000, 23, 57-76.	1.4	96
92	Lessons from lipodystrophy:LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophy. <i>Aids</i> , 2000, 14, 1854-1855.	1.0	15
93	ApoE genotype and protease-inhibitor-associated hyperlipidaemia. <i>Lancet, The</i> , 1999, 354, 76.	6.3	38
94	Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. <i>Aids</i> , 1999, 13, F63-F70.	1.0	454
95	Lipid Evaluation in HIV-1-Positive Patients Treated with Protease Inhibitors. <i>Antiviral Therapy</i> , 1999, 4, 163-170.	0.6	33
96	Highly active antiretroviral therapy. <i>Lancet, The</i> , 1998, 351, 1057-1058.	6.3	30
97	Vascular complications associated with use of HIV protease inhibitors. <i>Lancet, The</i> , 1998, 351, 1958.	6.3	201
98	Healthcare Workers' Perceptions and Medically Approved COVID-19 Infection Risk: Understanding the Mental Health Dimension of the Pandemic. A German Hospital Case Study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	4